There is disclosed a chimeric infliximab-like monoclonal antibody having at least 80% NANA glycosylation terminal sialic acid and a glycosylation pattern of Gal-α(2, 3/6)-Gal that binds to tumor necrosis factor alpha (TNF). The disclosed infliximab-like monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of SEQ ID NO. 1/SEQ ID NO. 2) as infliximab (Remicade®) which has at least 80% NGNA terminal sialic acid and a glycosylation pattern of Gal-α(1, 3)-Gal.